| Firm |
Analyst |
| Aegis Capital |
Ram Selvaraju, Ph.D., MBA |
| Canaccord |
John Neumann, Ph.D. |
| Citigroup |
Yaron Werber, M.D. |
| Cowen and Company |
Phil Nadeau, Ph.D. |
| FBR Capital Markets |
William Tanner, Ph.D. |
| ISI Group |
Mark Schoenebaum, M.D. |
| JPMorgan |
Geoff Meacham, Ph.D. |
| Leerink Swann |
Marko Kozul |
| MKM Partners |
Jon LeCroy, M.D. |
| Piper Jaffray Co. |
David Amsellem |
| RBC Capital Markets |
Michael Yee |
| Robert W. Baird & Co. |
Christopher J. Raymond |
| Stifel Nicolaus |
Joel Sendek |
Acorda Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Acorda Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Acorda Therapeutics, Inc. or its management. Acorda Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.